JP2023029966A5 - - Google Patents

Download PDF

Info

Publication number
JP2023029966A5
JP2023029966A5 JP2022194564A JP2022194564A JP2023029966A5 JP 2023029966 A5 JP2023029966 A5 JP 2023029966A5 JP 2022194564 A JP2022194564 A JP 2022194564A JP 2022194564 A JP2022194564 A JP 2022194564A JP 2023029966 A5 JP2023029966 A5 JP 2023029966A5
Authority
JP
Japan
Prior art keywords
guide
seq
nucleotides
sequence
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022194564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023029966A (ja
JP7707140B2 (ja
Filing date
Publication date
Priority claimed from JP2020517500A external-priority patent/JP2021500864A/ja
Application filed filed Critical
Publication of JP2023029966A publication Critical patent/JP2023029966A/ja
Publication of JP2023029966A5 publication Critical patent/JP2023029966A5/ja
Priority to JP2025112164A priority Critical patent/JP2025163016A/ja
Application granted granted Critical
Publication of JP7707140B2 publication Critical patent/JP7707140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022194564A 2017-09-29 2022-12-06 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法 Active JP7707140B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112164A JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762566236P 2017-09-29 2017-09-29
US62/566,236 2017-09-29
US201862671902P 2018-05-15 2018-05-15
US62/671,902 2018-05-15
JP2020517500A JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
PCT/US2018/053382 WO2019067872A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR EDITING THE TTR GENE AND TREATING AMYLOID DOSE ATTR

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020517500A Division JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112164A Division JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Publications (3)

Publication Number Publication Date
JP2023029966A JP2023029966A (ja) 2023-03-07
JP2023029966A5 true JP2023029966A5 (enExample) 2023-06-02
JP7707140B2 JP7707140B2 (ja) 2025-07-14

Family

ID=63858214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517500A Pending JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
JP2022194564A Active JP7707140B2 (ja) 2017-09-29 2022-12-06 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020517500A Pending JP2021500864A (ja) 2017-09-29 2018-09-28 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスの治療用の組成物および方法

Country Status (16)

Country Link
US (4) US20200248180A1 (enExample)
EP (1) EP3688161A1 (enExample)
JP (3) JP2021500864A (enExample)
KR (1) KR20200058509A (enExample)
CN (2) CN111417728A (enExample)
AU (2) AU2018338787C1 (enExample)
BR (1) BR112020005287A2 (enExample)
CA (1) CA3077251A1 (enExample)
CO (1) CO2020005116A2 (enExample)
IL (3) IL311170B2 (enExample)
MX (2) MX2020003608A (enExample)
MY (1) MY203849A (enExample)
PH (1) PH12020550364A1 (enExample)
SG (1) SG11202002565YA (enExample)
TW (1) TWI904069B (enExample)
WO (1) WO2019067872A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2021011690A (es) * 2019-03-28 2022-01-06 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
MX2021011757A (es) * 2019-03-28 2021-12-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la expresión de polipéptidos.
KR20220004648A (ko) * 2019-03-28 2022-01-11 인텔리아 테라퓨틱스, 인크. Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
WO2020247452A1 (en) * 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
AU2020401206A1 (en) * 2019-12-11 2022-07-14 Intellia Therapeutics, Inc. Modified guide RNAs for gene editing
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
EP4259792A1 (en) 2020-12-11 2023-10-18 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing involving deamination
CN112795595A (zh) * 2020-12-24 2021-05-14 中山大学 一种遗传性转甲状腺素蛋白淀粉样变性疾病的基因治疗系统
CA3220738A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
WO2022271780A1 (en) 2021-06-22 2022-12-29 Intellia Therapeutics, Inc. Methods for in vivo editing of a liver gene
WO2023028469A2 (en) * 2021-08-23 2023-03-02 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ， インコーポレイテッド インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
CN116064598B (zh) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
CN118974256A (zh) * 2022-03-29 2024-11-15 锐正基因(苏州)有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
WO2024003805A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Methods and compositions for ttr gene editing and therapy using crispr system
WO2024003810A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Guide rna with chemical modifications
CN118853659A (zh) * 2023-04-14 2024-10-29 深圳瑞吉生物科技有限公司 提高mRNA翻译蛋白的输出量的核酸及其应用
EP4728093A1 (en) 2023-06-13 2026-04-22 Intellia Therapeutics, Inc. Assays for analysis of ribonucleic acid (rna) molecules
KR20260094824A (ko) * 2023-10-25 2026-06-23 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 고효율, 저오프타겟 유전자 편집 도구
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026149586A1 (en) * 2025-01-13 2026-07-16 Geneditbio Limited Compositions comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent and methods using the same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
EP2323667A4 (en) 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
JP5723378B2 (ja) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
UA118649C2 (uk) 2011-11-18 2019-02-25 Елнілем Фармасьютікалз, Інк. ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
SG11201510327TA (en) * 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015183026A1 (ko) * 2014-05-28 2015-12-03 주식회사 툴젠 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법
DK3161128T3 (en) * 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US10369232B2 (en) * 2015-09-21 2019-08-06 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
US11866727B2 (en) * 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
WO2017093804A2 (en) * 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
US11083799B2 (en) * 2016-03-16 2021-08-10 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas

Similar Documents

Publication Publication Date Title
JP2021500864A5 (enExample)
IL311170A (en) Compositions and methods for ttr gene editing and treating attr amyloidosis
US20250025580A1 (en) Compositions and Methods for Treatment of Diseases Associated with Trinucleotide Repeats in Transcription Factor Four
JP2020501582A5 (enExample)
JP2022525428A5 (enExample)
AU749410B2 (en) In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
US6096720A (en) Liposomal oligonucleotide compositions
JP2002534353A (ja) 高脂血症の遺伝子治療のための方法および化合物
RS54944B1 (sr) Oligonukleotidi za pravljenje promena u sekvencama ciljanih rnk molekula prisutnih u živoj ćeliji
JP2017510583A (ja) 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
KR20200011899A (ko) 인위적인 유전자 조작을 통한 자가면역질환 치료
WO2025166988A1 (zh) 一种肾脏靶向mRNA-LNP递送技术和疾病治疗方法
TW202444910A (zh) 編碼casx之信使rna
WO2021141917A1 (en) Antisense oligonucleotides for treatment of neurological disorders
JP2001511171A (ja) 安定化したカチオン性トランスフェクション用物質／核酸粒子の配合物
CN111133110A (zh) 用于重复扩增突变的基因组编辑系统
WO2024036186A2 (en) Identification of allele-specific target sequences for c9orf72
JPWO2004026343A1 (ja) 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤
NZ762942B2 (en) Compositions and methods for ttr gene editing and treating attr amyloidosis
WO2026008077A1 (en) Modified grna for gene editing using crispr/cas system
WO2025128134A1 (en) Crispri targeting alpha-synuclein
US20020137717A1 (en) Use of chimeric mutational vectors to change endogenous nucleotide sequences in solid tissues
HK40127532A (en) Sirna duplex for targeted regulation of lpa gene expression and their use in preventing and treating cardiovascular and cerebrovascular related diseases
HK40127532B (en) Sirna duplex for targeted regulation of lpa gene expression and their use in preventing and treating cardiovascular and cerebrovascular related diseases
WO2022035984A1 (en) Antisense oligonucleotides for treatment of conditions and diseases related to trem2